COVID-19 vaccine
Enable an AI agent to identify a COVID-19 vaccine, assess its documented suitability and physical usability, and determine which handling or use decisions require current product-specific evidence and authority.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
recalled by Codex without web access - no source was read
Researched by: Codex
Purpose and description
Enable an AI agent to identify a COVID-19 vaccine, assess its documented suitability and physical usability, and determine which handling or use decisions require current product-specific evidence and authority.
A COVID-19 vaccine is a biological preparation designed to induce immune protection against disease caused by SARS-CoV-2, particularly severe illness, by presenting viral antigens or instructions for producing them.
It can be Identify a physical supply against product, formulation, presentation and lot documentation.; Compare antigen compositions and presentations without assuming products are interchangeable.; Assess recorded storage and preparation history against the applicable product instructions.; Flag a supply for quarantine or expert review when identity, integrity or usable-dose status is unresolved.; Retrieve current jurisdiction-specific conditions of use and supporting evidence.; Trace a lot to quality notices, recalls or safety investigations..
Distinguishing features
The preparation is intended to elicit active immunity against SARS-CoV-2; direct antiviral action or delivery of preformed antibodies does not establish membership.
Its intended indication includes prevention of COVID-19; being a vaccine against another infection is insufficient.
An antigen sequence, research reagent or platform description alone is not a COVID-19 vaccine preparation.
Investigational status and marketing authorization are separate from identity: a candidate preparation can belong to this kind without being authorized for routine use.
A named vaccine product, a composition update, a lot and an individual dose are distinct levels of identity within this kind.
Scope
+ Vaccine platform, antigen composition and intended immune target
+ Product, formulation, presentation, lot and dose identity
+ Manufacturing quality, lot release and documented integrity
+ Storage, transport, preparation and usable-dose conditions
+ Product-specific evidence, safety information and authorized conditions of use
- SARS-CoV-2 biology, variant classification and COVID-19 disease models
- Individual patient records, diagnoses and vaccination histories
- Vaccination encounters and administration procedures as clinical activities
- Population vaccination programmes, procurement systems and allocation policies
- Standalone delivery devices and general cold-chain infrastructure
- Other vaccines, passive antibody products and antiviral medicines
Characteristics
- Vaccine platform
- Documented platform, such as mRNA, viral vector, protein subunit or inactivated virus; other or unknown Distinguishes how the preparation supplies or expresses its immune target and which product-specific constraints need investigation.
- Antigen composition
- References to documented antigen components, target sequences or strains, and composition version Separates formulations that share a product family name but differ in intended immune targets.
- Presentation
- Product-documented container, dosage form, concentration and nominal dose count Determines how the physical supply is recognized and prepared.
- Dose specification
- Volume in mL and active-component quantity in the units specified for the formulation Prevents confusion among formulation concentration, container content and administered dose.
- Product and lot traceability
- Manufacturer, product identifier, formulation identifier, lot number and supporting records Connects a physical supply to release documentation, expiry information and applicable notices.
- Storage and excursion history
- Temperature records in °C, durations with time units, handling events and product-specific excursion assessments Supports an evidence-based assessment of whether recorded handling permits further use.
- Preparation state
- Product-applicable states such as unopened, thawed, diluted, punctured, prepared or discarded Identifies which handling rules and remaining-use limits apply.
- Applicable use-by limit
- Date and time with time zone, linked to expiry and any shorter handling-dependent limit Makes the basis and timing of physical usability explicit.
- Regulatory status
- Jurisdiction- and date-specific status with authority and documentary reference Prevents an authorization in one setting or period from being treated as universal.
- Evidence-supported use
- Links to population, regimen, comparator, outcome, follow-up period and safety evidence Keeps claims about benefit and risk attached to the conditions actually studied.
Also called
+18
Where this came from
wikidata · CC0 1.0
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 6 bundles · 11 layers · 19 findings · 29 questions.
Vaccine identity and composition Establishes which COVID-19 vaccine preparation is represented and how its immune-targeting composition is distinguished.
A shared COVID-19 indication or product family name does not uniquely identify a formulation.
Platform and immune target
Describes the preparation's platform and intended antigenic target.
Active immunization identity
Record the documented basis for classifying the preparation as a COVID-19 vaccine and its platform.
- What preparation and platform are intended to induce active immunity against SARS-CoV-2? definition
- What distinguishes this preparation from an antigen reagent, passive antibody product or antiviral medicine? boundary
Composition and formulation version
Separates antigen updates and formulation differences within a vaccine product family.
Documented composition
Record antigen components, relevant excipients and the version of the formulation being represented.
- Which antigen components and target sequences or strains define this composition? definition
- Which manufacturer or regulatory document identifies this formulation and distinguishes it from earlier or parallel versions? provenance
Presentation and lot assurance Connects the vaccine's physical presentation to dose specifications, manufacturing identity and lot disposition.
Formulation mix-ups and lot-specific quality issues cannot be resolved using the generic vaccine name.
Container and dose specification
Identifies the container contents and the documented relationship between concentration, preparation and dose.
Presentation-specific dose
Record presentation identifiers and dose quantities without generalizing across formulations.
- What dosage form, container, concentration and nominal dose count identify this presentation? definition
- What volume and active-component quantity define a dose for each documented use of this formulation? measurement
Lot traceability and release
Links a vaccine lot to its origin, release evidence and subsequent quality disposition.
Lot quality disposition
Record evidence of lot identity and whether its documented quality status permits distribution or use.
- Which records connect this lot to the manufacturer, formulation, expiry assignment and applicable release decision? provenance
- Does a quality notice, suspected falsification, recall or unresolved release status require this lot to be held for review? action
Cold chain and dose usability Represents the handling history and state transitions that determine whether a physical vaccine supply remains usable.
Printed expiry alone cannot establish usability after storage changes or preparation.
Storage and excursion assessment
Relates observed transport and storage conditions to the exact presentation's documented limits.
Temperature history assessment
Record temperature evidence, gaps and any authorized assessment of excursions.
- What temperature ranges and durations were recorded during transport and storage, and where are records missing? measurement
- Which product-specific instructions or documented expert assessment determine the disposition of any excursion? action
Preparation and use-by state
Tracks applicable preparation events and the time limits they trigger.
Remaining usability
Determine the applicable use-by limit from documented preparation history and product instructions.
- Which applicable thawing, dilution, puncture or preparation events occurred, at what times and under what conditions? measurement
- Given those events, expiry information and observed integrity, may the supply remain available or must it be held or discarded? action
Protection and safety evidence Organizes evidence about immune responses, clinical protection and adverse outcomes without detaching claims from their study conditions.
COVID-19 vaccine evidence depends on composition, circulating variants, population, regimen and elapsed time.
Immune response and clinical outcomes
Distinguishes laboratory immune measurements from evidence about clinical outcomes.
Bounded protection claims
Record each protection claim with its endpoint, study context and uncertainty.
- Does the evidence measure an immune response, infection, symptomatic disease, hospitalization or another specified outcome? definition
- What estimate and uncertainty apply to which formulation, population, regimen, variant context and follow-up interval? measurement
Adverse outcomes and signal assessment
Separates observed events after vaccination from assessed adverse reactions and unresolved signals.
Qualified safety evidence
Record safety findings with the population, exposure denominator, observation window and assessment status.
- Which study or surveillance assessment supports each safety concern, and how does it address causality? provenance
- What frequency or comparative risk is reported for which formulation, dose sequence, population and observation window? measurement
Authorized use and decision boundaries Connects the vaccine to dated regulatory conditions, recommendations and limits on automated interpretation.
Physical usability, regulatory authorization and suitability for a particular recipient require distinct evidence.
Jurisdiction and product status
Identifies the exact formulation's regulatory position in a specified place and period.
Dated regulatory basis
Record the responsible authority, operative decision and conditions attached to the product.
- Which authority and dated document establish this formulation's status in the relevant jurisdiction? provenance
- What populations, indications and conditions are covered, and what uses fall outside that document? boundary
Regimen and recipient interface
Links product-specific use conditions to external clinical assessment without owning a patient's care plan.
Use conditions and review
Record applicable regimen guidance, contraindications and precautions with their sources and effective dates.
- Which current documents specify dose intervals, prior-vaccination handling, interchangeability, contraindications and precautions for this formulation? provenance
- Which missing recipient details or conflicting instructions require clinical review before a use decision can be made? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- This is recalled knowledge, not source-verified research.
- Current formulations, authorizations and vaccination recommendations require jurisdiction-specific verification.
- Dose volumes, storage conditions and adverse-event frequencies must be checked against the exact product and age-specific formulation.
- Which of these check these first hold for the sense of COVID-19 vaccine this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Messenger RNA vaccines
- Non-replicating viral vector vaccines
- Protein subunit vaccines
- Inactivated whole-virus vaccines
- DNA vaccines
- Virus-like particle vaccines
- Which of these kinds and varieties hold for the sense of COVID-19 vaccine this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- WHO Anatomical Therapeutic Chemical classification - J07BN - Group for COVID-19 vaccines; individual vaccine categories have more specific codes.
- Manufacturer lot or batch number - Manufacturer-assigned alphanumeric identifier - Identifies a production batch for traceability and recalls, rather than the vaccine class.
- Which of these identifiers and schemes hold for the sense of COVID-19 vaccine this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- WHO Technical Report Series 1004, Annex 9: Good manufacturing practices for biological products.
- United States FDA: biological product licensing requirements under 21 CFR Part 601.
- European Commission: EudraLex Volume 4, Annex 2, governing manufacture of biological active substances and medicinal products.
- Which of these standards and regulation hold for the sense of COVID-19 vaccine this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Active immunization to reduce COVID-19 illness, hospitalization and death.
- Initial vaccination courses and subsequent doses under applicable public health recommendations.
- Use of updated antigen formulations to improve protection against circulating viral variants.
- Vaccination programmes prioritizing populations at increased risk of severe disease.
- Which of these real-world use hold for the sense of COVID-19 vaccine this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Volume administered per intramuscular injection - Common presentations use 0.2-0.5; the exact volume depends on product, formulation and age group - mL
- Which of these typical measurements hold for the sense of COVID-19 vaccine this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Breakthrough infection can occur because protection against infection is incomplete, wanes over time and varies with viral evolution.
- Storage excursions, incorrect dilution or use beyond an allowed storage interval can compromise product quality.
- Administration errors can involve the wrong formulation, dose volume, route or schedule.
- Transient injection-site pain, fatigue, headache and fever can occur; severe allergic reactions are rare.
- Rare adverse events vary by platform and product, including myocarditis or pericarditis after mRNA vaccination and thrombosis with thrombocytopenia after certain adenoviral vector vaccines.
- Which of these failure modes and hazards hold for the sense of COVID-19 vaccine this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Authorized products, eligible age groups and recommended schedules differ by jurisdiction.
- Available vaccine platforms and formulations differ with procurement, manufacturing capacity and storage infrastructure.
- National regulators determine authorization; WHO emergency use listing is a separate assessment.
- Which of these regional variation hold for the sense of COVID-19 vaccine this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Vaccine - The broader class targets many pathogens or diseases; this subclass specifically targets SARS-CoV-2 to prevent COVID-19.
- COVID-19 antiviral medicine - An antiviral directly inhibits viral processes; a vaccine induces an immune response.
- SARS-CoV-2 monoclonal antibody product - An antibody product supplies passive immunity; a vaccine stimulates active immunity.
- COVID-19 vaccine product - A named product has a particular manufacturer, composition and authorization; this entry covers the vaccine class.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of COVID-19 vaccine this model covers, and on what evidence? provenance
What the second pass must settle
- Does an existing Vercy vaccine or COVID-19 vaccine world model already own this concept, requiring a registry link instead of a separate publication?
- Which authoritative product documents should anchor the initial coverage of platforms, antigen compositions and presentation variants?
- How should composition updates and age-specific formulations be identified consistently when product naming differs across jurisdictions?
- Which current sources establish formulation-specific storage limits, excursion disposition rules and preparation-dependent use-by limits?
- Where does evidence remain insufficient to transfer protection, safety or interchangeability conclusions between formulations, populations or variant contexts?